Skip to main content
SpringerLink
Log in

Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Since iron overload is the commonest cause of morbidity and mortality in β thalassemia major (β-TM), it represents one major target in therapeutic management of the disease. The recently discovered erythroid regulator, erythroferrone (ERFE), governed by high levels of erythropoietin, was found to suppress hepcidin expression, thus increasing iron availability for developing erythroid progenitors. We aimed to investigate ERFE levels in Egyptian β-TM patients as an attempt to understand its role in the prediction of iron overload states. Our study included 70 β-TM patients, divided into two subgroups according to the degree of iron overload, and 30 sex and age-matched healthy subjects. ERFE gene expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR), and serum hepcidin was measured using enzyme-linked immunosorbent assay (ELISA) technique. Both ERFE gene expression levels and transferrin saturation (TS%) values were able to discriminate among cases with different degrees of iron overload, in contrast to hepcidin. TS% was acknowledged as the best predictor of iron overload (AUC 0.893) in comparison with serum hepcidin and ERFE gene levels (AUC 0.807 and 0.677, respectively), and ERFE gene expression was an independent predictor for the estimated TS%. In conclusion, we suggest that using the ERFE gene expression, combined with serum hepcidin estimation, can substantiate the role of estimated TS% as a promising tool in screening for iron overload in β-TM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Origa R (2017) Beta-thalassemia. Genetics in Medicine 19:609–619

    Article  CAS  Google Scholar 

  2. Adly A, Ebeid F (2015) Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt. J Pediatr Hematol Oncol 37(4):281–284

    Article  Google Scholar 

  3. Sherief L, Abd El-Salam S, Kamal N et al (2014) Nutritional biomarkers in children and adolescents with beta-thalassemia-major: an Egyptian center experience. Biomed Res Int 2014:261761

    Article  Google Scholar 

  4. El-Shanshory M, Hagag A, Shebl S et al (2014) Spectrum of beta globin gene mutations in Egyptian children with β-thalassemia. Mediterr J Hematol Infect Dis 6(1):e2014071

    Article  Google Scholar 

  5. Elmezayen A, Kotb S, Sadek N et al (2015) β-Globin mutations in Egyptian patients with β-thalassemia. Lab Med 46(1):8–13

    Article  Google Scholar 

  6. Hoffbrand A, Taher A, Cappellini M (2012) How I treat transfusional iron overload. Blood. 120(18):3657–3669

    Article  CAS  Google Scholar 

  7. Olivieri N, Nathan D, MacMillan J, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR (1994) Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331:574–578

    Article  CAS  Google Scholar 

  8. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B (2000) Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 110:971–977

    Article  CAS  Google Scholar 

  9. Puliyel M, Sposto R, Berdoukas V, Hofstra TC, Nord A, Carson S, Wood J, Coates TD (2014) Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol 89(4):391–394

    Article  CAS  Google Scholar 

  10. Musallam K, Cappellini M, Wood J, Motta I, Graziadei G, Tamim H, Taher AT (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 96(11):1605–1612

    Article  CAS  Google Scholar 

  11. Wood J (2014) Guidelines for quantifying iron overload. ASH Education Book 1:210–215

    Google Scholar 

  12. Jacobs E, Hendriks J, van Tits B, Evans PJ, Breuer W, Liu DY, Jansen EH, Jauhiainen K, Sturm B, Porter JB, Scheiber-Mojdehkar B, von Bonsdorff L, Cabantchik ZI, Hider RC, Swinkels DW (2005) Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal Biochem 341(2):241–250

    Article  CAS  Google Scholar 

  13. Wood J (2007) Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol 82(12 Suppl):1132–1135

    Article  CAS  Google Scholar 

  14. Kautz L, Jung G, Valore E, Rivella S, Nemeth E, Ganz T (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46(7):678–684

    Article  CAS  Google Scholar 

  15. Pasricha S, McHugh K, Drakesmith H (2016) Regulation of hepcidin by erythropoiesis: the story so far. Annu Rev Nutr 36:417–434

    Article  CAS  Google Scholar 

  16. Moura I, Hermine O (2015) Erythroferrone: the missing link in β-thalassemia? Blood 126(17):1974–1975

    Article  CAS  Google Scholar 

  17. Koury M. Erythroferrone: a missing link in iron regulation. The Hematologist. 2015;12(1):10

  18. Musallam K, Taher A, Rachmilewitz E (2013) β-Thalassemia intermedia: a clinical perspective. Cold Spring Harbor perspectives in medicine 2(7):a013482

    Google Scholar 

  19. Shander A, Cappellini M, Goodnough L (2009) Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang 97(3):185–197

    Article  CAS  Google Scholar 

  20. Wang W, Knovich M, Coffman L et al (2010) Serum ferritin: past, present and future. Biochim Biophys Acta 1800(8):760–769

    Article  CAS  Google Scholar 

  21. Shander A, Sazama K (2010) Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 50(5):1144–1155

    Article  CAS  Google Scholar 

  22. Mishra A, Tiwari A (2013) Iron overload in beta thalassaemia major and intermedia patients. Maedica 8(4):328

    PubMed  PubMed Central  Google Scholar 

  23. Chauhan R, Sharma S, Chandra J (2014) What regulates hepcidin in poly-transfused β-thalassemia major: erythroid drive or store drive? Indian J Pathol Microbiol 57(1):39

    Article  Google Scholar 

  24. Kaddah A, Abdel-Salam A, Farhan M, Ragab R (2017) Serum hepcidin as a diagnostic marker of severe iron overload in beta-thalassemia major. The Indian Journal of Pediatrics 84(10):745–750

    Article  Google Scholar 

  25. Eissa D, El-Gamal R (2014) Iron overload in transfusion-dependent β-thalassemia patients: defining parameters of comorbidities. The Egyptian Journal of Haematology 39(3):164–170

    Article  Google Scholar 

  26. Kautz L, Jung G, Du X et al (2015) Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood 126:2031–2037

    Article  CAS  Google Scholar 

  27. Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E (2016) Clinical trials update in new treatments of β-thalassemia. Am J Hematol 91(11):1135–1145

    Article  CAS  Google Scholar 

  28. Jiang X, Gao M, Chen Y et al (2016) EPO-dependent induction of erythroferrone drives hepcidin suppression and systematic iron absorption under phenylhydrazine-induced hemolytic anemia. Blood Cell Mol Dis 58:45–51

    Article  CAS  Google Scholar 

  29. Ravasi G, Pelucchi S, Trombini P, Mariani R, Tomosugi N, Modignani GL, Pozzi M, Nemeth E, Ganz T, Hayashi H, Barisani D, Piperno A (2012) Hepcidin expression in iron overload diseases is variably modulated by circulating factors. PLoS One 7(5):e36425

    Article  CAS  Google Scholar 

  30. Aboul-Enein A, El-Beshlawy A, Hamdy M et al (2015) Peripheral expression of hepcidin gene in Egyptian β-thalassemia major. Gene. 564(2):206–209

    Article  CAS  Google Scholar 

  31. Galesloot T, Vermeulen S, Geurts-Moespot A et al (2011) Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 117(25):218–225

    Article  Google Scholar 

  32. Haghpanah S, Esmaeilzadeh M, Honar N, Hassani F, Dehbozorgian J, Rezaei N, Abdollahi M, Bardestani M, Safaei S, Karimi M (2015) Relationship between serum hepcidin and ferritin levels in patients with thalassemia major and intermedia in Southern Iran. Iran Red Crescent Med J 17(7):e28343

    PubMed  PubMed Central  Google Scholar 

  33. Cheng P, Jiao X, Wang X, Lin JH, Cai YM (2011) Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia. Clin Exp Med 11(1):33–42

    Article  Google Scholar 

  34. D'Angelo G (2013) Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood research 48(1):10–15

    Article  CAS  Google Scholar 

  35. Pratummo K, Jetsrisuparb A, Fucharoen S, Tripatara A (2014) Hepcidin expression from monocyte of splenectomized and non-splenectomized patients with HbE-β-thalassemia. Hematology 19(3):175–180

    Article  CAS  Google Scholar 

  36. Kaddah N, El-Gindi H, Mostafa N et al (2011) Role of hepcidin in the pathogenesis of iron overload in children with β-thalassemia. International Journal of Academic Research 3(4):62–69

    Google Scholar 

  37. Hendy O, Allam M, Allam A et al (2010) Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis c virus infection. The Egyptian Journal of Immunology 17(2):33–44

    PubMed  Google Scholar 

  38. Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, Yamamoto T, Tomosugi N, Shibata T (2016) Associations among erythroferrone and biomarkers of erythropoiesis and Iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One 11(3):e0151601. https://doi.org/10.1371/journal.pone.0151601

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Schrier S, Bacon B. Clinical manifestations and diagnosis of hereditary hemochromatosis. UpToDate. 2016. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-hereditary-hemochromatosis. last updated Jan 25, 2018

  40. Porto G, Brissot P, Swinkels D, Zoller H, Kamarainen O, Patton S, Alonso I, Morris M, Keeney S (2016) EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet 24(4):479–495

    Article  CAS  Google Scholar 

  41. Danjou F, Cabantchik Z, Origa R, Moi P, Marcias M, Barella S, Defraia E, Dessì C, Foschini ML, Giagu N, Leoni GB, Morittu M, Galanello R (2014) A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica. 99(3):e38–e40

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Abbasseya, Cairo, 11566, Egypt

    Rasha Abd El-Rahman El-Gamal, Ibrahim Youssef Abdel-Messih, Deena Mohamed Habashy, Shams Eldoha Galal Zaiema & Shaimaa Abdelmalik Pessar

Authors
  1. Rasha Abd El-Rahman El-Gamal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ibrahim Youssef Abdel-Messih
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deena Mohamed Habashy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shams Eldoha Galal Zaiema
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaimaa Abdelmalik Pessar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaimaa Abdelmalik Pessar.

Ethics declarations

Verbal consent was taken from all participants or their guardians sharing in this study according to the ethical committee regulations of Ain Shams University.

Conflict of interest

The author declares that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Gamal, R.A.ER., Abdel-Messih, I.Y., Habashy, D.M. et al. Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia. Ann Hematol 99, 31–39 (2020). https://doi.org/10.1007/s00277-019-03882-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03882-w

Keywords

Search

Navigation